Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin).

Fifty-five patients with carcinoma in situ of the bladder have been treated with intravesical Adriamycin, the longest follow-up being over 2.5 years. Side-effects were negligible. Primary carcinoma in situ shows the highest overall response rate, with over 80%, followed by secondary carcinoma in situ with no tumours, with 67%; in the presence of active tumour only 25% of patients treated showed any real improvement. Adriamycin is recommended for the conservative management of primary carcinoma in situ.